![]() |
市场调查报告书
商品编码
1764841
2031年亚太细胞和基因治疗市场预测—区域分析—按类型、服务、规模、服务提供者和最终用户Asia Pacific Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type, Services, Scale, Service Providers, and End User |
2023 年亚太细胞和基因治疗市值为 10.2437 亿美元,预计到 2031 年将达到 80.1275 亿美元;预计 2023 年至 2031 年的复合年增长率为 29.3%。
公司策略措施推动亚太细胞和基因治疗市场
许多参与细胞和基因治疗产品生产的公司专注于合作、扩张、协议、伙伴关係、新产品发布和其他策略发展。这些策略倡议有助于他们提高销售额、扩大地理覆盖范围并增强服务庞大客户群的能力。细胞和基因治疗市场的一些重要发展包括:2023年9月,安捷伦科技公司与新加坡先进细胞治疗与研究中心(ACTRIS)签署了一份谅解备忘录(MOU)。该协议旨在未来三年推动细胞和基因治疗领域的进步。 2023年3月,Cellevolve Bio与西雅图儿童治疗公司合作,开发并商业化用于治疗儿童癌症的新型多重嵌合抗原受体(CAR)药物。透过此次合作,两家公司将专注于BrainChild研究计画——一套由五种多重CAR组成的方案——用于治疗儿童中枢神经系统(CNS)恶性肿瘤。他们计划利用西雅图儿童治疗工厂的设施进行新型CAR的早期临床GMP研究。 2023年3月,Twist Bioscience Corporation与Kriya Therapeutics, Inc.达成一项抗体发现协议,旨在开发利用腺相关病毒(AAV)基因疗法递送的抗体,用于肿瘤治疗应用。此外,两家公司还计划将Twist的抗体库与Kriya专有的载体工程平台结合,以发现针对特定标靶的新型抗体,并利用Kriya的基因治疗技术进行递送。 2023年1月,富士软片株式会社同意收购Atara Biotherapeutics, Inc.旗下的一家细胞疗法生产厂。该工厂将进行扩建,以灵活地生产临床和商业细胞疗法,例如同种异体T细胞和CAR-T免疫疗法。透过合作和伙伴关係开展新业务以保持市场竞争力,有助于加速开发新的细胞和基因疗法生产服务平台。因此,预计主要参与者的这些策略倡议将在预测期内为亚太细胞和基因疗法市场创造巨大的成长机会。
亚太细胞和基因治疗市场概览
中国在基因和细胞治疗领域正在取得进展。中国拥有庞大的患者群体,这对于开发此类疗法的公司来说是一个极具吸引力的市场。中国多家公司正在研发针对癌症和遗传性疾病等疾病的创新疗法,并在基因治疗研发方面投入了大量资金。中国于2003年成为首个批准基因治疗的国家;自此之后,全球细胞和基因治疗发展迅速,其治疗潜力也大幅提升。中华人民共和国政府已实施多项监管改革,以促进细胞和基因治疗的规范发展。根据2021年发表在《自然》杂誌上的一项研究,全球超过50%的细胞治疗试验在中国进行。中国目前有近400项CAR-T试验正在进行中,主要针对血液学、肿瘤学和实体肿瘤。随着復星凯特的Yescarta和药明巨诺的Relma-cel于2021年获得国家药品监督管理局(NMPA)的批准,中国的细胞治疗正迈入一个新时代。 2023年10月,科济生物和信达生物分别获得国家药品监督管理局(NMPA)批准,获得针对B细胞成熟抗原的CAR-T疗法新药上市许可。预计这些疗法将很快获得批准并实现商业化。
亚太细胞及基因治疗市场收入及预测(2031年)(百万美元)
亚太细胞和基因治疗市场细分
亚太细胞和基因治疗市场按类型、服务、规模、最终用户和国家分类。
根据类型,亚太细胞和基因治疗市场分为细胞治疗和基因治疗。 2023年,细胞治疗占据了更大的市场。此外,细胞治疗细分市场又细分为同种异体载体、自体载体和病毒载体。基因治疗细分市场又细分为非病毒载体和病毒载体。
就服务而言,亚太细胞和基因治疗市场分为製程开发、cGMP製造、监管服务和生物测定服务。製程开发领域在2023年占据了最大的市场。
按规模划分,亚太地区细胞和基因治疗市场分为商业化前/研发生产和商业化规模生产。 2023年,商业化前/研发生产领域占据了更大的市场份额。
根据最终用户,亚太细胞和基因治疗市场细分为合约研究组织、製药和生物製药公司以及学术和研究机构。製药和生物製药公司在2023年占据了最大的市场。
按国家/地区划分,亚太细胞和基因治疗市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。 2023年,中国占据了亚太细胞和基因治疗市场的主导地位。
Catalent Inc、Charles River Laboratories International Inc、F. Hoffmann-La Roche Ltd、FUJIFILM Holdings Corp、Lonza Group AG、乐天公司、默克集团、Takara Bio Inc、赛默飞世尔科技公司和药明康德股份有限公司是亚太细胞和基因治疗市场的一些领先公司。
The Asia Pacific cell and gene therapy market was valued at US$ 1,024.37 million in 2023 and is projected to reach US$ 8,012.75 million by 2031; it is estimated to record a CAGR of 29.3% from 2023 to 2031.
Strategic Initiatives by Companies Drive Asia Pacific Cell and Gene Therapy Market
Many companies involved in manufacturing cell and gene therapy products focus on collaborations, expansions, agreements, partnerships, new product launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance capacities to cater to a large customer base. A few of the significant developments in the cell and gene therapy market are; In September 2023, Agilent Technologies Inc. signed a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). This agreement aims to improve cell and gene therapy advancements over the next three years. In March 2023, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program-a suite of five multiplex CARs-to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs. In March 2023, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Also, the companies aim to combine Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology. In January 2023, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility will witness expansion with the flexibility to produce clinical as well as commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies. The initiation of new businesses to remain competitive in the market through collaborations and partnerships can help accelerate the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives by key players are anticipated to create substantial growth opportunities in the Asia Pacific cell and gene therapy market during the forecast period.
Asia Pacific Cell and Gene Therapy Market Overview
China is making progress in gene and cell therapy. The country has a large patient population making it an attractive market for companies developing these treatments. Several companies are working on innovative therapies for diseases such as cancer and genetic disorders in China, and the country has invested heavily in gene therapy research and development. China was the first country to approve gene therapy in 2003; since then, cell and gene therapy developments have advanced rapidly worldwide, and their therapeutic potential has soared. The government of the People's Republic of China has conducted several regulatory reforms to promote the normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials worldwide. China has nearly 400 ongoing CAR-T trials centered on hematology, oncology, and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite's Yescarta and JW Therapeutics' Relma-cel in 2021 from the National Medical Products Administration (NMPA). In October 2023, CARsgen and IASO Biotherapeutics/Innovent were approved by the NMPA for new drug approvals targeting B-cell maturation antigens in CAR-T. These therapies are expected to be approved and commercialized soon.
Asia Pacific Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)
Asia Pacific Cell and Gene Therapy Market Segmentation
The Asia Pacific cell and gene therapy market is categorized into type, services, scale, end user, and country.
Based on type, the Asia Pacific cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.
In terms of services, the Asia Pacific cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.
By scale, the Asia Pacific cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.
Based on end user, the Asia Pacific cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.
By country, the Asia Pacific cell and gene therapy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific cell and gene therapy market share in 2023.
Catalent Inc, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy market.